Company intelligence / Profile preview

Roivant Sciences

New York City, New York, United Statesen.wikipedia.org ↗
Ownership
Public · ROIV
Employees
~950
Development stage
Commercial
01

Overview

Since its founding in 2014, Roivant has achieved ten positive Phase III trials since 2019 and eight FDA approvals through its Vant companies. Its first commercial launch was VTAMA® cream in plaque psoriasis. The company continues to advance a broad pipeline spanning multiple therapeutic areas with several late-stage clinical programs[1][2][4].

Therapeutic areas
PulmonologyRheumatologyOphthalmologyEndocrinologyDermatologyNeurology
Modalities
Small moleculesbiologics (including monoclonal antibodies)gene therapiesother modalities across its subsidiaries
Industry
Biotech
02

Drug pipeline

2 assets

gimsilumab

2

1 more asset in the full pipeline.

Request access →
03

Partnerships

Numerous R&D partnerships with biopharma industry players and academic institutions; specific partners not detailed in search results but known to collaborate widely on R&D solutions
04

Financials

Market cap
$30B
Total revenue
$1.4M
Enterprise value
$26.2B

Beyond the preview

Go deeper on Roivant Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Roivant Sciences.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call